In one paragraphArticle in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Alexander J KwiatkowskiDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Jacob A SchulmanDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Hayden M PagendarmDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0001-7611-6120 Lucinda E PastoraDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0009-0006-2409-6360 John T TossbergDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Ruilin ZhangDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Neil C ChadaDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0003-4566-3564 Mia E WoodruffDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0009-0004-2719-2791 Taylor L SheehyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0002-3100-8115 Karan AroraDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
John KarijolichDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Thomas M AuneDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
John T WilsonDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0002-9144-2634 Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9MMULTIDISCIPLINARY BASIC RESEARCH TRAINING IN CANCERT32CA009592 · NCI · VANDERBILT UNIVERSITY · PI Justin M Balko, Julie A Rhoades (Sterling) · 1987 to 2026
$10.4MMedical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8MIntegrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9MEngineered Vaccines for Neoantigen Targeted Cancer ImmunotherapyR01CA266767 · NCI · VANDERBILT UNIVERSITY · PI John Tanner Wilson · 2022 to 2026
$2.4MRIG-I Activating Nanoparticles for ImmunopotentiationR01EB033822 · NIBIB · VANDERBILT UNIVERSITY · PI Anna Marie Pyle, John Tanner Wilson · 2022 to 2026
$2.4MEngineering RIG-I Activating Nanoparticles for Glioblastoma ImmunotherapyF32CA288044 · NCI · VANDERBILT UNIVERSITY · PI Alexander Kwiatkowski · 2024 to 2026
$227kNCI NIH HHS F32 CA288044NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA266767NCI NIH HHS T32 CA009592NIBIB NIH HHS R01 EB033822NIDDK NIH HHS P30 DK058404NIDDK NIH HHS T32 DK101003NIGMS NIH HHS T32 GM152284
6 · The paper itselfAbstract
Vaccine adjuvants stimulate innate immunity to enhance and shape adaptive immune responses. However, approved adjuvants typically elicit weak CD8
Indexed as
Adjuvants, ImmunologicAdjuvants, VaccineAlu ElementsCancer VaccinesImmunogenicity, VaccineNanoparticlesRNAAnimalsCD8-Positive T-LymphocytesFemaleHumansMiceMice, Inbred C57BLAdjuvants, ImmunologicAdjuvants, VaccineCancer VaccinesRNAadjuvantAlu RNAA-to-I editingendosomal escapenanoparticles
Identifiers
PMID40878005
PMCPMC12442014
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390